Binnaz Zeynep Yıldırım
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Binnaz Zeynep Yıldırım has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Demet Turan
Department of Pulmonology, Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, University of Health Sciences, Istanbul, Türkiye
7 shared publications - Efsun Gonca Uğur Chousein
Department of Pulmonology, Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, University of Health Sciences, Istanbul, Türkiye
6 shared publications - Elif Tanrıverdi
Department of Pulmonology, Yedikule Pulmonary Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey
6 shared publications - Mehmet Akif Özgül
Basaksehir Cam and Sakura City Hospital, Department of Pulmonology, Istanbul, Turkey
6 shared publications - Erdoğan Çetinkaya
Department of Chest Disease, Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, University of Health Sciences, Istanbul, Turkey
5 shared publications - Halit Çınarka
Department of Chest Diseases, University of Health Sciences, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkiye
5 shared publications
Latest Publications
- Open Access
- 1 April 2025
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (2) , 217-225
The efficacy of topical mitomycin-C in the treatment of benign tracheal stenosis: A comparative study
Background: This study aims to examine the efficacy of mitomycin-C (MMC) in patients with benign tracheal stenosis who have re-stenosis requiring repeated interventional bronchoscopy. Methods: Between January 2009 and December 2019, a total of 25 patients who underwent repeated procedures for re-stenosis were retrospectively analyzed. The study group consisted of 11 patients (7 males, 4 females; median age: 37 years; range, 16 to 63 years) who underwent MMC following routine dilation and the control group consisted of 14 patients (8 males, 6 females; median age: 52 years; range, 19 to 73 years) who underwent dilation alone and did not receive MMC. Demographic data of the patients, the etiology of stenosis, comorbidities, medications used, imaging studies, location, degree and length of re-stenosis, details of interventional bronchoscopy, pre- and post-procedural time intervals between mechanical dilation, and cost were reviewed. Results: The percentage changes of re-stenosis and mean re-stenotic segment length significantly decreased (p=0.013 and p=0.029, respectively), and the medical cost (p=0.021), and number of repeated dilations (p=0.020) were lower in the MMC-treated group, compared to the control group. However, the improvement rate was not significantly different (p=0.070) between the MMC-treated group and control group. Conclusion: Mitomycin-C is helpful to decrease the tracheal re-stenosis percentage changes and the number of repeated dilations in patients with benign tracheal stenosis. It also decreases the median re-stenotic segment lengths which may be crucial for limited reserve surgery in tracheal resections. Taken together, MMC is a cost-effective, time-saving and tracheal-sparing treatment in patients with benign tracheal stenosis.
- 1 April 2025
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (2) , 217-225
Open AccessThe efficacy of topical mitomycin-C in the treatment of benign tracheal stenosis: A comparative study
Background: This study aims to examine the efficacy of mitomycin-C (MMC) in patients with benign tracheal stenosis who have re-stenosis requiring repeated interventional bronchoscopy. Methods: Between January 2009 and December 2019, a total of 25 patients who underwent repeated procedures for re-stenosis were retrospectively analyzed. The study group consisted of 11 patients (7 males, 4 females; median age: 37 years; range, 16 to 63 years) who underwent MMC following routine dilation and the control group consisted of 14 patients (8 males, 6 females; median age: 52 years; range, 19 to 73 years) who underwent dilation alone and did not receive MMC. Demographic data of the patients, the etiology of stenosis, comorbidities, medications used, imaging studies, location, degree and length of re-stenosis, details of interventional bronchoscopy, pre- and post-procedural time intervals between mechanical dilation, and cost were reviewed. Results: The percentage changes of re-stenosis and mean re-stenotic segment length significantly decreased (p=0.013 and p=0.029, respectively), and the medical cost (p=0.021), and number of repeated dilations (p=0.020) were lower in the MMC-treated group, compared to the control group. However, the improvement rate was not significantly different (p=0.070) between the MMC-treated group and control group. Conclusion: Mitomycin-C is helpful to decrease the tracheal re-stenosis percentage changes and the number of repeated dilations in patients with benign tracheal stenosis. It also decreases the median re-stenotic segment lengths which may be crucial for limited reserve surgery in tracheal resections. Taken together, MMC is a cost-effective, time-saving and tracheal-sparing treatment in patients with benign tracheal stenosis.
- 6 October 2023
- Published by Galenos Yayinevi in Hamidiye Medical Journal
- Vol. 4 (1) , 22-27
The Diagnostic Value of Procalcitonin in Differentiation of Exacerbation and Pneumonia in Patients with Idiopathic Pulmonary Fibrosis
- 6 October 2023
- Published by Galenos Yayinevi in Hamidiye Medical Journal
- Vol. 4 (1) , 22-27
The Diagnostic Value of Procalcitonin in Differentiation of Exacerbation and Pneumonia in Patients with Idiopathic Pulmonary Fibrosis
- 24 June 2021
- Published by Academician Publishing
Olgular ile Plevra Hastalıkları ve Cerrahi Tedavisi
Değerli Meslektaşlarımız, Plevra hastalıkları, günümüzde insidansı giderek artan ve hem göğüs hastalıkları hem de göğüs cerrahisi kliniklerinin pratiğinde yaygın bir iş yükü oluşturan sorun halinde karşımıza çıkmaktadır. Çok geniş sebeplere dayalı bir dağılım gösteren plevra patolojilerinin tanı ve tedavi yöntemi multidisipliner yaklaşım gerekmektedir. Bu konuyla ilgili çıkarılan eserler oldukça değerli teorik bilgiler içermekle birlikte pratik ve vaka noktasında bilgi birikimini gerektiği ölçüde yansıtmadığı gözlenmektedir. Bu düşünceden yola çıkarak, plevral hastalıkları ve cerrahi tedavi yaklaşımını olgu sunumları eşliğinde özetleyen alanında bu yönüyle ilk eser olan bu kitabı değerli okuyucularımıza sunmaktan gurur duyuyoruz. Bu eserde günümüzdeki plevra patolojilerine yaklaşım, güncel tanı rehberleri ve cerrahi tedavideki yenilikler, göğüs hastalıkları ve göğüs cerrahisi alanlarında kürsü sahibi olan değerli hocalarımız tarafından olgular eşliğinde işlenmiştir. Klinik tecrübelerin kanıta dayalı yöntemlerle aktarıldığı, vakaların güncel pratiğimizde rehberlik edeceği bir kaynak olarak titizlikle hazırlanmıştır. Eserin tüm bölümlerinin hazırlık aşamasında emeği geçen kıymetli hocalarımıza ayrı ayrı şükranlarımızı sunarız. Kıymetli meslektaşlarımıza faydalı olması temennisiyle…. Kızlarımız Zülal, Elif, Defne, Gökçen ve tüm sağlık çalışanlarının çocuklarına armağan olması dileğiyle
- 24 June 2021
- Published by Academician Publishing
Olgular ile Plevra Hastalıkları ve Cerrahi Tedavisi
Değerli Meslektaşlarımız, Plevra hastalıkları, günümüzde insidansı giderek artan ve hem göğüs hastalıkları hem de göğüs cerrahisi kliniklerinin pratiğinde yaygın bir iş yükü oluşturan sorun halinde karşımıza çıkmaktadır. Çok geniş sebeplere dayalı bir dağılım gösteren plevra patolojilerinin tanı ve tedavi yöntemi multidisipliner yaklaşım gerekmektedir. Bu konuyla ilgili çıkarılan eserler oldukça değerli teorik bilgiler içermekle birlikte pratik ve vaka noktasında bilgi birikimini gerektiği ölçüde yansıtmadığı gözlenmektedir. Bu düşünceden yola çıkarak, plevral hastalıkları ve cerrahi tedavi yaklaşımını olgu sunumları eşliğinde özetleyen alanında bu yönüyle ilk eser olan bu kitabı değerli okuyucularımıza sunmaktan gurur duyuyoruz. Bu eserde günümüzdeki plevra patolojilerine yaklaşım, güncel tanı rehberleri ve cerrahi tedavideki yenilikler, göğüs hastalıkları ve göğüs cerrahisi alanlarında kürsü sahibi olan değerli hocalarımız tarafından olgular eşliğinde işlenmiştir. Klinik tecrübelerin kanıta dayalı yöntemlerle aktarıldığı, vakaların güncel pratiğimizde rehberlik edeceği bir kaynak olarak titizlikle hazırlanmıştır. Eserin tüm bölümlerinin hazırlık aşamasında emeği geçen kıymetli hocalarımıza ayrı ayrı şükranlarımızı sunarız. Kıymetli meslektaşlarımıza faydalı olması temennisiyle…. Kızlarımız Zülal, Elif, Defne, Gökçen ve tüm sağlık çalışanlarının çocuklarına armağan olması dileğiyle
- Open Access
- 15 March 2021
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 39 (2) , 148-152
Frequency of Direct Oral Anticoagulants Usage in Acute Pulmonary Thromboembolism Treatment in Turkey (TUPEDO)
Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic range, and necessary close International Normalized Ratio (INR) monitoring. Phase 3 study results have reported that these drugs are at least as effective as warfarin and beneficial in terms of bleeding; however, studies that present up-to-date life data are necessary. Aims: To evaluate the frequency of using DOACs, which are prescribed with a limited number of indications in our country, and real-life data results. Study Design: Cross-sectional study Methods: This cross-sectional survey collected the clinical data (history, current treatment, treatment duration, etc.) of patients with pulmonary thromboembolism and who applied to the physician for follow-up between October 15, 2019, and March 15, 2020. The researchers kept the patient records sequentially. Results: Data from 836 patients with acute pulmonary thromboembolism from 25 centers were collected, and DOAC was used in 320 (38.5%) of them. The most preferred DOAC was rivaroxaban (n = 294, 91.9%). DOAC was mostly preferred because it could not provide an effective INR level with warfarin (n=133, 41.6%). Bleeding was observed in 13 (4%) patients. Conclusion: The use of direct oral anticoagulants is becoming almost as widespread as conventional therapy. Real-life data results are important for their contribution to clinical practice.
- 15 March 2021
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 39 (2) , 148-152
Open AccessFrequency of Direct Oral Anticoagulants Usage in Acute Pulmonary Thromboembolism Treatment in Turkey (TUPEDO)
Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic range, and necessary close International Normalized Ratio (INR) monitoring. Phase 3 study results have reported that these drugs are at least as effective as warfarin and beneficial in terms of bleeding; however, studies that present up-to-date life data are necessary. Aims: To evaluate the frequency of using DOACs, which are prescribed with a limited number of indications in our country, and real-life data results. Study Design: Cross-sectional study Methods: This cross-sectional survey collected the clinical data (history, current treatment, treatment duration, etc.) of patients with pulmonary thromboembolism and who applied to the physician for follow-up between October 15, 2019, and March 15, 2020. The researchers kept the patient records sequentially. Results: Data from 836 patients with acute pulmonary thromboembolism from 25 centers were collected, and DOAC was used in 320 (38.5%) of them. The most preferred DOAC was rivaroxaban (n = 294, 91.9%). DOAC was mostly preferred because it could not provide an effective INR level with warfarin (n=133, 41.6%). Bleeding was observed in 13 (4%) patients. Conclusion: The use of direct oral anticoagulants is becoming almost as widespread as conventional therapy. Real-life data results are important for their contribution to clinical practice.
- Open Access
- 26 February 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (1) , 10-15
Hydroxychloroquine plus azithromycin and early hospital admission are beneficial in COVID-19 patients: Turkish experience with real-life data
New treatment regimens for COVID-19, which threatened the world recently, continue to be investigated. Although some of the treatments are promising, it is thought to be early to clearly state that there is definitive treatment. Experiences and treatment protocols studies coming from the centers are still very important. The aim of this study is to evaluate factors affecting the treatment process in the first cases followed in our clinic. The consecutive hospitalized patients with COVID-19 pneumonia were analyzed in this retrospective and cross-sectional study. Datas were recorded from the electronic and written files of patients. Eighty three patients were evaluated. The median age was 50±15 years. Fourty eight (57.8%) patients had one or more comorbidities. The most common comorbidity was hypertension. The most common symptom was cough in 58 patients (70%). The overall mortality was 15% and 85% of the patients were discharged. The time between the onset of symptoms and hospitalization was statistically significantly longer in deceased patients (p=0,039). Age, D-Dimer, troponin, creatine kinase (CK), CK-MB, ferritin, procalcitonin, and neutrophil to lymphocyte ratio were statistically significantly higher in deceased patients than survivor patients. Performed subgroup analysis, in the patients receiving azithromycin plus hydroxychloroquine and other antibiotics plus hydroxychloroquine, the duration of hospitalization was shorter in azithromycin group (p=0,027). Early treatment and early admission to the hospital can be crucial for the better treatment process. Combination therapy with azithromycin may be preferred in the first treatment choice because it can shorten the length of hospital stay.
- 26 February 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (1) , 10-15
Open AccessHydroxychloroquine plus azithromycin and early hospital admission are beneficial in COVID-19 patients: Turkish experience with real-life data
New treatment regimens for COVID-19, which threatened the world recently, continue to be investigated. Although some of the treatments are promising, it is thought to be early to clearly state that there is definitive treatment. Experiences and treatment protocols studies coming from the centers are still very important. The aim of this study is to evaluate factors affecting the treatment process in the first cases followed in our clinic. The consecutive hospitalized patients with COVID-19 pneumonia were analyzed in this retrospective and cross-sectional study. Datas were recorded from the electronic and written files of patients. Eighty three patients were evaluated. The median age was 50±15 years. Fourty eight (57.8%) patients had one or more comorbidities. The most common comorbidity was hypertension. The most common symptom was cough in 58 patients (70%). The overall mortality was 15% and 85% of the patients were discharged. The time between the onset of symptoms and hospitalization was statistically significantly longer in deceased patients (p=0,039). Age, D-Dimer, troponin, creatine kinase (CK), CK-MB, ferritin, procalcitonin, and neutrophil to lymphocyte ratio were statistically significantly higher in deceased patients than survivor patients. Performed subgroup analysis, in the patients receiving azithromycin plus hydroxychloroquine and other antibiotics plus hydroxychloroquine, the duration of hospitalization was shorter in azithromycin group (p=0,027). Early treatment and early admission to the hospital can be crucial for the better treatment process. Combination therapy with azithromycin may be preferred in the first treatment choice because it can shorten the length of hospital stay.
- Open Access
- 1 January 2021
- Published by European Publishing in Pneumon
- Vol. 34 (1) , 1-9
Interventional bronchoscopic management of recalcitrant adenoid cystic carcinoma obstructing central airways
INTRODUCTION Adenoid cystic carcinoma (ACC) of the lung is a rare tumor with a propensity to cause central airway obstruction. Prolonged patient survival with high recurrence rates despite surgery, oncologic treatment or interventional bronchoscopic procedures (IBPs) poses long-term management challenges. With this study we aimed to review IBPs and their outcome in patients with ACC. METHODS We retrospectively reviewed the demographics, bronchoscopic findings, IBP treatment modalities and outcomes of patients with a diagnosis of ACC between January 2009 and December 2020. RESULTS There were 13 patients (9 male, 69.2%) with a mean age of 54.61 +/- 8.7 years. Trachea was the most involved site (10 cases, 76.9%) and percentage of obstruction was 77 +/- 13.9%. Bronchoscopy most commonly identified an endoluminal lesion (84.6%). There was a total of 77 procedures, including 44 rigid and 31 flexible bronchoscopies. Seven patients underwent a single procedure and 6 patients more than one procedure. Most common interventional bronchoscopic treatment modalities used were argon plasma coagulation (40.2%) and mechanical resection (38.9%). Airway stents were inserted in 4 (30.7%) patients. Airway patency was restored following first-line IBP in 93% of patients. The rate of early complications within the first 24 hours was 6.8%. Late complications were seen in 33.7% and were all stent related. No procedure related mortality was observed. CONCLUSIONS ACC affects central airways and most frequently the trachea. IBPs can be repeatedly used in the treatment of ACC because of their low early complication rates. Patients treated with airway stents should be closely followed up for late complications.
- 1 January 2021
- Published by European Publishing in Pneumon
- Vol. 34 (1) , 1-9
Open AccessInterventional bronchoscopic management of recalcitrant adenoid cystic carcinoma obstructing central airways
INTRODUCTION Adenoid cystic carcinoma (ACC) of the lung is a rare tumor with a propensity to cause central airway obstruction. Prolonged patient survival with high recurrence rates despite surgery, oncologic treatment or interventional bronchoscopic procedures (IBPs) poses long-term management challenges. With this study we aimed to review IBPs and their outcome in patients with ACC. METHODS We retrospectively reviewed the demographics, bronchoscopic findings, IBP treatment modalities and outcomes of patients with a diagnosis of ACC between January 2009 and December 2020. RESULTS There were 13 patients (9 male, 69.2%) with a mean age of 54.61 +/- 8.7 years. Trachea was the most involved site (10 cases, 76.9%) and percentage of obstruction was 77 +/- 13.9%. Bronchoscopy most commonly identified an endoluminal lesion (84.6%). There was a total of 77 procedures, including 44 rigid and 31 flexible bronchoscopies. Seven patients underwent a single procedure and 6 patients more than one procedure. Most common interventional bronchoscopic treatment modalities used were argon plasma coagulation (40.2%) and mechanical resection (38.9%). Airway stents were inserted in 4 (30.7%) patients. Airway patency was restored following first-line IBP in 93% of patients. The rate of early complications within the first 24 hours was 6.8%. Late complications were seen in 33.7% and were all stent related. No procedure related mortality was observed. CONCLUSIONS ACC affects central airways and most frequently the trachea. IBPs can be repeatedly used in the treatment of ACC because of their low early complication rates. Patients treated with airway stents should be closely followed up for late complications.
- 30 March 2020
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 68 (1) , 17-24
Real life results of coil treatment for bronchoscopic lung volume reduction in emphysema
Introduction: The lung volume reduction coil treatment is a minimally invasive bronchoscopic treatment option for emphysema patients who suffer from severe hyperinflation. Previous studies have reported successful outcomes in selected cases using coil for bronchoscopic lung volume reduction (BLVR). Our aim is to determine the changes in respiratory function tests, perception of dyspnea and exercise capacities after 12 months in patients treated with endobronchial coil. Materials and Methods: The data of patients with severe emphysema and treated with coils between 2014-2017 were evaluated retrospectively. Dynamic and static lung volume capacities at baseline and 12 months, modified Medical Research Council (mMRC) questionnaire and six-minute walk test (6-MWT) results were recorded. Results: BLVR was performed in thirty patients (one female, twenty-nine males). Five patients were treated bilaterally and twentyfive unilaterally. One patient died after 7 days and 4 patients died during follow-up. Five patients were lost to follow-up. A total of twenty patients with available data were included in the study. A statistically significant difference was found in mMRC results in pre-treatment and 12-month evaluations. There was no significant difference in FEV1, TLC and RV values at the end of 12 months. There was an increase of 18.9 meters ( +/- 83.5 m) between the baseline and 12 months in 6-MWT 45% of the patients improved their walking distance over 26 meters which is known as minimal clinically important difference (MCID). Conclusion: Although no significant changes were observed in pulmonary function tests and lung volumes, the increase in exercise capacity and decreased perception of dyspnea indicate the efficacy of endobronchial coil.
- 30 March 2020
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 68 (1) , 17-24
Real life results of coil treatment for bronchoscopic lung volume reduction in emphysema
Introduction: The lung volume reduction coil treatment is a minimally invasive bronchoscopic treatment option for emphysema patients who suffer from severe hyperinflation. Previous studies have reported successful outcomes in selected cases using coil for bronchoscopic lung volume reduction (BLVR). Our aim is to determine the changes in respiratory function tests, perception of dyspnea and exercise capacities after 12 months in patients treated with endobronchial coil. Materials and Methods: The data of patients with severe emphysema and treated with coils between 2014-2017 were evaluated retrospectively. Dynamic and static lung volume capacities at baseline and 12 months, modified Medical Research Council (mMRC) questionnaire and six-minute walk test (6-MWT) results were recorded. Results: BLVR was performed in thirty patients (one female, twenty-nine males). Five patients were treated bilaterally and twentyfive unilaterally. One patient died after 7 days and 4 patients died during follow-up. Five patients were lost to follow-up. A total of twenty patients with available data were included in the study. A statistically significant difference was found in mMRC results in pre-treatment and 12-month evaluations. There was no significant difference in FEV1, TLC and RV values at the end of 12 months. There was an increase of 18.9 meters ( +/- 83.5 m) between the baseline and 12 months in 6-MWT 45% of the patients improved their walking distance over 26 meters which is known as minimal clinically important difference (MCID). Conclusion: Although no significant changes were observed in pulmonary function tests and lung volumes, the increase in exercise capacity and decreased perception of dyspnea indicate the efficacy of endobronchial coil.
- 1 July 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (4) , 356-359
A Case of Sarcoidosis with Diffuse Cavitary Lesion in the Lung
- 1 July 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (4) , 356-359
A Case of Sarcoidosis with Diffuse Cavitary Lesion in the Lung